Not yet recruitingPhase NA

Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication

A Single Arm Trial to Evaluate the Effect of PhytoMulti® Multivitamin and UltraFlora® Balance Probiotic on Bowel Symptoms in Individuals Using GLP-1 Receptor Agonists, Assessed by the IBS Symptom Severity Score (IBS-SSS)

Lead sponsor

Metagenics, Inc.

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Estimated enrollment

100

Study population

Eligibility highlights

•BMI 25-30

Primary endpoint

•IBS- SSS

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07130396

Org study IDGLO-NAM-2025-02

Timeline

Milestones

Study first posted2025-08-19actual

Last update posted2025-08-19actual

Study start2025-11-01estimated

Primary completion2026-03-31estimated

Study completion2026-04-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

1. Providing written informed consent

2. Males and females of at least 18 years old

3. Minimum 4 weeks on GLP-1 (f.e Ozempic®, Wegovy®, Mounjaro®, etc.) and maximum 1 year on GLP-1

4. Body Mass Index (BMI) ≥ 25 AND ≤ 30

5. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period

6. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).

Exclusion criteria

1. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.

2. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and/or being immunocompromised.

3. Suffering from any uncontrolled endocrine disorder

4. Having used any antibiotic treatment in the 2 months prior to enrollment.

5. Having a known allergy to the ingredients in the study product.

6. Being pregnant or lactating (breastfeeding) or trying to become pregnant.

7. Participating in another clinical trial.

8. Suffering from dementia or inability to take the trial treatment in an appropriate way.

9. Taking PhytoMulti® Multivitamin and/or UltraFlora® Probiotic or any similar product from competitors prior to trial participation

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

IBS- SSS

Time frame:From enrollment to the end of treatment at 12 weeks (90 days)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.